Shire acquire NPS Pharmaceuticals $5.2 billion

Shire to acquire NPS Pharmaceuticals for $5.2 billion

11:15 AM, 12th January 2015
Shire to acquire NPS Pharmaceuticals for $5.2 billion

DUBLIN, IRELAND/BEDMINSTER, US: Shire plc and NPS Pharmaceuticals, Inc announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion. Shire will accelerate the growth of NPS Pharma’s innovative portfolio through its market expertise in gastrointestinal (GI) disorders, core capabilities in rare disease patient management, and global footprint. The transaction has been approved unanimously by the Boards of Directors of both Shire and NPS Pharma. The $46.00 per share price in the transaction represents a 51 per cent premium to NPS Pharma’s unaffected share price of $30.47 on 16 December 2014.

“The acquisition of NPS Pharma is a significant step in advancing Shire’s strategy to become a leading biotechnology company. With our global strength and expertise in both rare diseases and GI, Shire is uniquely positioned to drive the continued success of GATTEX/REVESTIVE, and, if approved, commercialize NPS Pharma’s pipeline compound NATPARA/NATPAR. We look forward to accelerating the growth of the NPS Pharma portfolio based on our proven track record of maximizing value from acquired assets and commercial execution. The NPS Pharma organization will be a welcome addition to Shire as we continue to help transform the lives of patients with rare diseases,” said Flemming Ornskov, Chief Executive Officer, Shire.

 

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Developing light-activated nanocarrier to transport proteins into cells

CALIFORNIA, US: University of California, Santa Barbara’s (UCSB) Reich Group uses lasers to spatially and temporally control the release of a ta ...

Read more
AMRI to acquire Aptuit’s drug product development and aseptic clinical manufacturing businesses

ALBANY, US: Albany Molecular Research Inc (AMRI) has acquired the outstanding equity interests of Aptuit’s Glasgow, UK business and has entered ...

Read more
Nippon Shokubai closes manufacturing plant at Suita, Japan

TOKYO, JAPAN: Nippon Shokubai Co Ltd announced that at the end of 2014 it ceased manufacturing at its Suita Plant in the city of Suita, Japan, a produ ...

Read more
MeadWestvaco plans to separate specialty chemicals business

RICHMOND, US: MeadWestvaco Corporation (MWV), a global leader in packaging and packaging solutions, has approved a plan to fully separate its Specialt ...

Read more
Indorama to acquire Polyplex’s PET resin plant in Turkey

BANGKOK, THAILAND: Indorama Ventures PCL (IVL), one of the world’s foremost petrochemical producers, has reached a definitive agreement with Pol ...

Read more
Scientists create first new antibiotic in nearly three decades

LONDON, UK: In a massive breakthrough, scientists have created the first new antibiotic in more than three decades, Teixobactin, that can treat many c ...

Read more